Elite Pharmaceuticals, Inc.
ELTP
$0.40
-$0.021-4.99%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 1.31% | -1,892.17% | -81.48% | 370.82% | -95.27% |
| Total Depreciation and Amortization | -11.54% | -0.93% | 21.11% | 31.61% | 5.29% |
| Total Amortization of Deferred Charges | 0.00% | 0.00% | -- | -- | -- |
| Total Other Non-Cash Items | -16.08% | 388.05% | 113.18% | -733.11% | 127.34% |
| Change in Net Operating Assets | -14.05% | -139.87% | -104.63% | 393.49% | -151.95% |
| Cash from Operations | -173.02% | -53.67% | 52.65% | 186.23% | -912.67% |
| Capital Expenditure | 100.00% | 88.13% | -92.89% | 0.59% | -- |
| Sale of Property, Plant, and Equipment | -100.00% | 618.95% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 100.00% | -- | -- | -- |
| Cash from Investing | -100.00% | 101.06% | -312.12% | 0.59% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 39.79% | -83.36% | 56.38% | -966.49% | 79.05% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 39.79% | -83.36% | 51.60% | -861.17% | 79.05% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -208.94% | -11.68% | 0.88% | 145.72% | -581.85% |